NEW YORK, Nov. 21, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, announces that it has been appointed as Lead Counsel in Smith v. CV Sciences, Inc., et al., No. 2:18-cv-01602-JAD-PAL (D. Nev.) and Alvarado v. CV Sciences, Inc., et al., No. 2:18-cv-01709-JAD-GWF (D. Nev.), class actions alleging violations of the federal securities laws against CV Sciences, Inc. ("CV Sciences" or the "Company") (Other OTC:CVSI).
Specifically, the Smith and Alvarado actions allege violations of federal securities laws arising out of statements regarding the Company's patent application for CVSI-007, titled "Pharmaceutical Formulations Containing Cannabidiol and Nicotine For Treating Smokeless Tobacco Addiction." On August 20, 2018, Citron Research reported in a tweet that the United States Patent and Trademark Office had issued a final rejection of CV Science's patent application. On this news, CV Sciences' share price fell.
On November 15, 2018, United States District Judge Jennifer A. Dorsey consolidated the Smith and Alvarado actions, appointed a lead plaintiff, and appointed the Faruqi Firm as Lead Counsel.
If you purchased CV Sciences securities between June 19, 2017 and August 20, 2018, both dates inclusive, please contact the firm to discuss this matter with us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an email to [email protected]. You may also request more information by filling out the form on our website at www.faruqilaw.com/CVSI.
Faruqi & Faruqi, LLP also encourages anyone with information regarding CV Sciences' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
[email protected]
Telephone: (877) 247-4292 or (212) 983-9330
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE Faruqi & Faruqi, LLP
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article